BioCryst Pharm (BCRX) options active on cancelled investor presentation
BioCryst Pharmaceuticals (Nasdaq: BCRX) is recently up 67c to $9.98. In a statement on its website, BioCryst said: "Due to recent developments, BioCryst will not participate in the Oppenheimer & Co. conference Nov 4." In October the CDC issued an emergency use authorization for peramivir in certain adult and pediatric patients with H1N1 influenza who are admitted to the hospital. BCRX call option volume of 20,598 contracts compares to put volume of 4,074 contracts according to Track Data. Puts are more expensive than calls because BCRX is difficult to borrow. Paul Foster
You May Also Be Interested In
- Nokia (NOK) Volatility Up as Shares Bounce Off Multi-Year Lows; Loses Top Mobile Spot to Samsung
- CBOE Volatility Index (VIX) down 0.86 to 23.63; S&P 500 recently up 0.18%
- A123 Systems (AONE) Moves Lower on Light Volume; Volatility Pops
Create E-mail Alert Related Categories
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
